表紙
市場調査レポート

MediPoint:大動脈ステントグラフト - 南米市場の分析・予測

MediPoint: Aortic Stent Grafts - South America Analysis and Market Forecasts

発行 GlobalData 商品コード 320354
出版日 ページ情報 英文 185 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
MediPoint:大動脈ステントグラフト - 南米市場の分析・予測 MediPoint: Aortic Stent Grafts - South America Analysis and Market Forecasts
出版日: 2014年10月31日 ページ情報: 英文 185 Pages
概要

大動脈ステントグラフトは一般に、動脈瘤と呼ばれる動脈内の弱い部分を補強するために用いられます。1991年に導入されて以来、幅広く受け入れられ、利用されるようになりましたが、これはステントグラフトの設計における進歩と、さまざまな解剖学的特性に対応できるデバイスの多様性によるところが大きいと考えられています。現在では、その低侵襲性と回復時間の早さから、破裂動脈瘤の治療においてもこれらのデバイスが多く利用されています。

当レポートでは、南米地域の大動脈ステントグラフト市場について調査し、大動脈瘤の治療法、治療におけるガイドライン、モダリティ、アンメットニーズ、大動脈ステントグラフトの市場への各種影響因子および市場機会の分析、企業および企業間の取り組み、主要製品の概要、製品開発の動向、主要企業のプロファイル、市場収益の推移と予測などをまとめています。

第1章 目次

第2章 イントロダクション

第3章 産業概要

  • 概要
  • 適応症
    • 腹部大動脈瘤
    • 胸部大動脈瘤
    • 大動脈解離
  • 臨床的転帰
    • ライフスタイルの改善
    • 投薬
    • 観血療法
    • 血管内修復
  • 処置の動向
    • 南米
  • 市場へのアクセス
    • 導入
    • 法規制
    • 償還
  • 規制上の課題/リコール
  • 合併・契約・買収など
    • Medtronic、Covidienを買収
    • TriVascular、1億ドルのIPOを募集
    • Lombard Medical、米国でIPOを募集
    • TriVascular、Eシリーズで4000万ドルを調達
    • LifeTech Scientific、Medtronicと提携、など
  • 経済的影響
    • 動脈瘤の経済的影響
    • 大動脈瘤の治療費

第4章 アンメットニーズ

  • 合併症への対処
    • エンドリーク
    • 虚血性合併症
    • 四肢血栓症
    • 感染症
    • 胸部大動脈瘤における対麻痺
  • シールゾーン・ランディングゾーン
  • 短頚
  • コスト上の制約
  • ロープロファイルシステム
  • カスタマイズ開窓型ステントグラフト
  • 分枝ステントグラフト
  • 胸部血管動脈瘤修復のアンメットニーズ
  • 長期臨床データ

第5章 市場機会の分析

  • 新興市場
  • 胸部大動脈疾患市場
  • 医師のトレーニングプログラムの追加
  • 破壊的技術
  • 低侵襲性の動向

第6章 市場促進要因・障壁・代替

  • 推進因子:有病率の拡大
    • 真性糖尿病
    • 高血圧症
    • 肥満症
    • 喫煙
  • 推進因子:老化
  • 推進因子:画像
  • 推進因子:血管内療法による臨床的転帰の改善
  • 推進因子:時間の節約
  • 推進因子:患者の需要と認識
  • 推進因子:技術的発展
    • 特注の分枝・開窓型ステントグラフト
    • ロープロファイルデリバリーシステム
  • 推進因子:競合および技術革新の活発化
  • 障壁:ベンチャー資金のアベイラビリティ
  • 障壁:規制拡大の負担
  • 障壁:高い治療費
  • 障壁:長期的な有効性の証明
  • 障壁:過剰な撮像による被爆量の増加
  • 外科的な制約
  • 障壁:医療機器物品税
  • 代用:観血療法
  • 代用:チムニー技術 vs 開窓型グラフト

第7章 競合分析

  • 概要
  • 主な上市済み製品
    • 血管内動脈瘤修復および胸部血管内動脈瘤修復製品

第8章 パイプラインの分析

  • 概要
  • 製品プロファイル
    • Altura Medical Endograft
    • Cordis INCRAFT
    • EndoSpan Horizon
    • EndoSpan Nexus
    • MicroPort Scientific Castor分枝ステントグラフトシステム
    • BiFlow Medicalの新しいサイドブランチステント
    • Endoluminal Sciencesのエンドグラフトメカニズム
    • Medtronic Valiant Mona LSAステントグラフトシステム
    • Endologix Ventanaの開窓型ステントグラフト

第9章 注目の臨床試験

  • 概要
  • Altura Medical
  • Cook Medical
  • Gore Medical
  • テルモ
  • Endologix
  • TriVascular
  • Bolton Medical
  • Medtronic
  • Cordis Corporation

第10章 現在および将来の企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Cook Medical
    • Endologix
    • Gore Medical
    • Medtronic
    • テルモ
    • Altura Medical
    • Aptus Endosystems
    • Bolton Medical
    • Braile Biomedica
    • B. Braun
    • Cardiatis
    • LeMaitre Vascular
    • Lifetech Scientific
    • Getinge Group
    • Grikin Advanced Materials
    • Johnson & JohnsonのCordis Corporation
    • Jotec
    • Lombard Medical
    • MicroPort Scientific Corporation
    • Nano Endoluminal
    • TriVascular
    • Weike Medical Apparatus and Instrument
    • YTH Biological Material Scitech

第11章 市場の展望

  • 市場区分別
    • 血管内動脈瘤修復
    • 胸部血管内動脈瘤修復
  • 地域別
    • 南米

第12章 付録

図表

目次
Product Code: GDME1121CFR

Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient's native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Aortic aneurysms, as opposed to aneurysms found elsewhere in the body, are potentially very serious, as a burst aorta results in massive internal bleeding that can be fatal unless treated rapidly by an experienced emergency medical team. Since their introduction in patients in 1991, aortic stent graft devices have gained wide acceptance and availability, with their adoption fueled in great part by advances in stent-graft design and by a variety of devices for various anatomic features. Over time, these devices have gained traction for use in patients with ruptured aneurysms because they are minimally invasive and have shorter recovery times.

Brazil accounts for about 5% of the aortic stent grafts market, which is a substantial part of the world market. Moreover, Brazil is extremely dependent on imported products. Finally, the South American market is similar to that of China in that it also has a local marketplace of players that capitalize on the public sector by offering cheaper prices on products. As multinationals offer new products in these markets, the firms that will have an added edge will be the firms with local sales offices since within a year of a product launch, local manufacturing tends to replicate and sell the devices to the public healthcare organizations.

Scope

  • An overview of Aortic Stent Grafts, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized South America Aortic Stent Grafts market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for Aortic Stent Grafts.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the Aortic Stent Grafts sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

  • Understand the trends shaping and driving the South America Aortic Stent Grafts market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in South America Aortic Stent Grafts market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in South America Aortic Stent Grafts market landscape Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Industry Overview

  • 3.1. Overview
  • 3.2. Indications
    • 3.2.1. Aortic Abdominal Aneurysm
    • 3.2.2. Thoracic Aortic Aneurysm
    • 3.2.3. Aortic Dissection
  • 3.3. Clinical Outcomes
    • 3.3.1. Lifestyle Changes
    • 3.3.2. Medication
    • 3.3.3. Open Surgery
    • 3.3.4. Endovascular Repair
  • 3.4. Procedure Trends
    • 3.4.1. South America
  • 3.5. Market Access
    • 3.5.1. Adoption
    • 3.5.2. Regulation
    • 3.5.3. Reimbursement
  • 3.6. Regulatory Issues/Recalls
    • 3.6.1. Anaconda Back on the Market in March 2014 after a Voluntary Recall of Anaconda by Vascutek
    • 3.6.2. Terminated FDA's Class II Recall of TriVascular's Ovation Prime in April 2014
  • 3.7. Mergers, Deals, and Acquisitions
    • 3.7.1. Medtronic Acquires Covidien
    • 3.7.2. TriVascular Launches $100m Initial Public Offering
    • 3.7.3. Lombard Medical Pursues US Initial Public Offering
    • 3.7.4. TriVascular Raises $40m in Series E Financing
    • 3.7.5. LifeTech Scientific Creates Partnership with Medtronic
    • 3.7.6. LeMaitre Vascular Terminates Distribution Agreement with Endologix
    • 3.7.7. Jotec Enters Licensing Agreement with Hydromer
    • 3.7.8. Endologix Public Offering of Notes
    • 3.7.9. Aptus Endosystems Secures Financing
    • 3.7.10. Altura Medical Secures Financing
    • 3.7.11. Endologix Acquires Nellix Endovascular
  • 3.8. Economic Impact
    • 3.8.1. Economic Impact of Aneurysms
    • 3.8.2. Treatment Costs of Aortic Aneurysms

4. Unmet Needs

  • 4.1. Addressing the Complications
    • 4.1.1. Endoleaks
    • 4.1.2. Ischemic Complications
    • 4.1.3. Limb Thrombosis
    • 4.1.4. Infection
    • 4.1.5. Paraplegia in Thoracic Aortic Aneurysm
  • 4.2. The Seal and Landing Zone
  • 4.3. Short Neck
  • 4.4. Cost Containment
  • 4.5. More Low Profile Systems
  • 4.6. Customized Fenestrated Stent Grafts
  • 4.7. Multi-Branch Stent Grafts
  • 4.8. Thoracic Endovascular Aneurysm Repair Unmet Needs
  • 4.9. Long-Term Clinical Data

5. Market Opportunity Analysis

  • 5.1. Emerging Markets
  • 5.2. Thoracic Aortic Disease Market
  • 5.3. Addition of Physician Training Programs
  • 5.4. Disruptive Technologies
  • 5.5. Minimally Invasive Trend

6. Market Drivers, Barriers, and Substitutes

  • 6.1. Driver: Rising Disease Prevalence
    • 6.1.1. Diabetes Mellitus
    • 6.1.2. Hypertension
    • 6.1.3. Obesity
    • 6.1.4. Tobacco Use
  • 6.2. Driver: Aging
  • 6.3. Driver: Imaging
  • 6.4. Driver: Improved Clinical Outcomes with Endovascular Therapy
  • 6.5. Driver: Time Savings
  • 6.6. Driver: Patient Demand and Awareness
  • 6.7. Driver: Technological Developments
    • 6.7.1. Custom Branched and Fenestrated Stent Grafts
    • 6.7.2. Low Profile Delivery Systems
  • 6.8. Driver: Rising Competition and Innovation
  • 6.9. Barrier: Availability of Venture Capital
  • 6.10. Barrier: Burden of Rising Regulation
  • 6.11. Barrier: High Treatment Cost
  • 6.12. Barrier: Proving Long-Term Efficacy
  • 6.13. Barrier: High Radiation Dosages with Excessive Imaging
  • 6.14. Surgical Limitations
  • 6.15. Barrier: Medical Device Excise Tax
  • 6.16. Substitute: Open Surgery
  • 6.17. Substitute: Chimney Technique versus Fenestrated Grafts

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Key Marketed Products
    • 7.2.1. Endovascular Aneurysm Repair and Thoracic Endovascular Aneurysm Repair Products

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Product Profiles
    • 8.2.1. Altura Medical Endograft
    • 8.2.2. Cordis INCRAFT
    • 8.2.3. EndoSpan Horizon
    • 8.2.4. EndoSpan Nexus
    • 8.2.5. MicroPort Scientific Castor Branched Stent Graft System
    • 8.2.6. BiFlow Medical Novel Side-Branch Stent
    • 8.2.7. Endoluminal Sciences Endograft Mechanism
    • 8.2.8. Medtronic Valiant Mona LSA Stent Graft System
    • 8.2.9. Endologix Ventana Fenestrated Stent Graft

9. Clinical Trials to Watch

  • 9.1. Overview
  • 9.2. Altura Medical
  • 9.3. Cook Medical
  • 9.4. Gore Medical
  • 9.5. Terumo Corporation
  • 9.6. Endologix
  • 9.7. TriVascular
  • 9.8. Bolton Medical
  • 9.9. Medtronic
  • 9.10. Cordis Corporation

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. Cook Medical
    • 10.3.2. Endologix
    • 10.3.3. Gore Medical
    • 10.3.4. Medtronic
    • 10.3.5. Terumo Corporation
    • 10.3.6. Altura Medical
    • 10.3.7. Aptus Endosystems
    • 10.3.8. Bolton Medical
    • 10.3.9. Braile Biomedica
    • 10.3.10. B. Braun
    • 10.3.11. Cardiatis
    • 10.3.12. LeMaitre Vascular
    • 10.3.13. Lifetech Scientific
    • 10.3.14. Getinge Group
    • 10.3.15. Grikin Advanced Materials
    • 10.3.16. Johnson & Johnson's Cordis Corporation
    • 10.3.17. Jotec
    • 10.3.18. Lombard Medical
    • 10.3.19. MicroPort Scientific Corporation
    • 10.3.20. Nano Endoluminal
    • 10.3.21. TriVascular
    • 10.3.22. Weike Medical Apparatus and Instrument
    • 10.3.23. YTH Biological Material Scitech

11. Market Outlook

  • 11.1. By Market Segment
    • 11.1.1. Endovascular Aneurysm Repair
    • 11.1.2. Thoracic Endovascular Aneurysm Repair
  • 11.2. By Geography
    • 11.2.1. South America

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Research Methodology
    • 12.3.1. Overview
    • 12.3.2. Coverage
    • 12.3.3. Secondary Research
  • 12.4. Physicians and Specialists Included in this Study
    • 12.4.1. Christopher Abularrage, MD, FACS
    • 12.4.2. Gaspar Mestres Alomar, MD
    • 12.4.3. Enio Buffolo, MD, PhD
    • 12.4.4. Ludovic Canaud, MD, PhD
    • 12.4.5. Holger Eggebrecht, MD
    • 12.4.6. Daisuke Fukui, MD, PhD
    • 12.4.7. Germano Melissano, MD
    • 12.4.8. Dr. Raghuram Sekhar MS, FRCS (Edinburgh), FRCS (Glasgow)
    • 12.4.9. Ferdinand Serracino-Inglott, MD, MSc, FRCSI, FRCS (Gen Surg), DIC
    • 12.4.10. Jiang Xiong, MD, PhD
  • 12.5. Primary Research
    • 12.5.1. Primary Research - Key Opinion Leader Interviews
    • 12.5.2. Primary Research - Physician and Industry Interviews
    • 12.5.3. Expert Panel Validation
  • 12.6. Forecasting Methodology
  • 12.7. About the Authors
    • 12.7.1. Analysts
    • 12.7.2. Global Head of Healthcare
  • 12.8. About MediPoint
  • 12.9. About GlobalData
  • 12.10. Disclaimer

List of Tables

  • Table 1: Summary of Indications, Symptoms, and Treatments
  • Table 2: Thoracic Aortic Aneurysm Types
  • Table 3: Medications for Reducing Risk of Aneurysm Growth and Rupture
  • Table 4: Advantages and Disadvantages of Open Repair versus Endovascular Repair
  • Table 5: Direct and Indirect Costs of Open Surgery and Endovascular Repair
  • Table 6: Comparison Costs and Other Variables for Treating AAA By Open Repair and Stent Grafts in 2012 ($US)
  • Table 7: Endoleak Types
  • Table 8: Zenith Family Marketed Products
  • Table 9: Zenith AAA SWOT
  • Table 10: Zenith TAA SWOT
  • Table 11: Endologix's Marketed Products
  • Table 12: AFX Endovascular SWOT
  • Table 13: IntuiTrak Powerlink System SWOT
  • Table 14: Gore Medical's Marketed Products
  • Table 15: Gore AAA Product SWOT
  • Table 16: Gore TAA Product SWOT
  • Table 17: Medtronic's Marketed Products
  • Table 18: Medtronic AAA Product SWOT
  • Table 19: Medtronic TAA Product SWOT
  • Table 20: Terumo Corporation Marketed Products
  • Table 21: Terumo Corporation AAA Product SWOT
  • Table 22: SWOT Analysis - Altura Medical Endograft
  • Table 23: SWOT Analysis - Cordis INCRAFT
  • Table 24: SWOT Analysis - EndoSpan Horizon
  • Table 25: SWOT Analysis - EndoSpan Nexus
  • Table 26: SWOT Analysis - MicroPort Scientific Castor Branched Stent Graft System
  • Table 27: SWOT Analysis - BiFlow Medical Novel Side-Branch Stent
  • Table 28: SWOT Analysis - Endoluminal Sciences Endograft Mechanism
  • Table 29: SWOT Analysis - Medtronic Valiant Mona LSA Stent Graft
  • Table 30: SWOT Analysis - Endologix Ventana Fenestrated Stent Graft
  • Table 31: Major Clinical Trials of Altura Medical's Aortic Stent Grafts
  • Table 32: Major Clinical Trials of Cook Medical's Aortic Stent Grafts
  • Table 33: Major Clinical Trials of Gore Medical's Aortic Stent Grafts
  • Table 34: Major Clinical Trials of Terumo's Aortic Stent Grafts
  • Table 35: Major Clinical Trials of Endologix's Aortic Stent Grafts
  • Table 36: Major Clinical Trials of TriVascular's Aortic Stent Grafts
  • Table 37: Major Clinical Trials of Bolton Medical's Aortic Stent Grafts
  • Table 38: Major Clinical Trials of Medtronic's Aortic Stent Grafts
  • Table 39: Major Clinical Trials of Cordis' Aortic Stent Grafts
  • Table 40: Company Profile - Cook Medical
  • Table 41: Cook Medical Marketed Products
  • Table 42: SWOT Analysis - Cook Medical
  • Table 43: Company Profile - Endologix Inc.
  • Table 44: Endologix Marketed Products
  • Table 45: Endologix Pipeline Products
  • Table 46: SWOT Analysis - Endologix Inc.
  • Table 47: Company Profile - Gore Medical
  • Table 48: Gore Medical Marketed Products
  • Table 49: SWOT Analysis - Gore Medical
  • Table 50: Company Profile - Medtronic
  • Table 51: Medtronic Marketed Products
  • Table 52: SWOT Analysis - Medtronic
  • Table 53: Company Profile - Terumo Corporation
  • Table 54:Terumo Corporation Marketed Products
  • Table 55: SWOT Analysis - Terumo Corporation
  • Table 56: Company Profile - Altura Medical Inc.
  • Table 57: Altura Medical Inc. Marketed Products
  • Table 58: SWOT Analysis - Altura Medical Inc.
  • Table 59: Company Profile - Aptus Endosystems, Inc.
  • Table 60: Aptus Endosystems Inc. Marketed Products
  • Table 61: SWOT Analysis - Aptus Endosystems Inc.
  • Table 62: Company Profile - Bolton Medical
  • Table 63: Bolton Medical Marketed Products
  • Table 64: SWOT Analysis - Bolton Medical
  • Table 65: Company Profile - Braile Biomedica
  • Table 66: Braile Biomedica Marketed Products
  • Table 67: SWOT Analysis - Braile Biomedica
  • Table 68: Company Profile - B. Braun
  • Table 69: B. Braun Marketed Products
  • Table 70: SWOT Analysis - B. Braun
  • Table 71: Company Profile - Cardiatis
  • Table 72: Cardiatis Marketed Products
  • Table 73: SWOT Analysis - Cardiatis
  • Table 74: Company Profile - LeMaitre Vascular
  • Table 75: LeMaitre Vascular Medical Marketed Products
  • Table 76: SWOT Analysis - LeMaitre Vascular
  • Table 77: Company Profile - Lifetech Scientific
  • Table 78: Lifetech Scientific Marketed Products
  • Table 79: SWOT Analysis - Lifetech Scientific
  • Table 80: Company Profile - Getinge Group
  • Table 81: Getinge Group Marketed Products
  • Table 82: SWOT Analysis - Getinge Group
  • Table 83: Company Profile - Grikin Advanced Materials
  • Table 84: Grikin Advanced Materials Marketed Products
  • Table 85: SWOT Analysis - Grikin Advanced Materials
  • Table 86: Company Profile - Johnson & Johnson Cordis Corporation
  • Table 87: Cordis Corporation's Pipeline Product
  • Table 88: SWOT Analysis - Cordis Corporation
  • Table 89: Company Profile - Jotec
  • Table 90: Jotec's Marketed Products
  • Table 91: SWOT Analysis - Jotec
  • Table 92: Company Profile - Lombard Medical
  • Table 93: Lombard Medical Marketed Products
  • Table 94: SWOT Analysis - Lombard Medical
  • Table 95: Company Profile - Microport Scientific Corporation
  • Table 96: MicroPort Scientific Marketed Products
  • Table 97: SWOT Analysis - MicroPort Scientific
  • Table 98: Company Profile - Nano Endoluminal
  • Table 99: Nano Endoluminal Medical Marketed Products
  • Table 100: SWOT Analysis - Nano Endoluminal
  • Table 101: Company Profile - TriVascular
  • Table 102: TriVascular Marketed Products
  • Table 103: SWOT Analysis - TriVascular
  • Table 104:South America Aortic Stent Grafts Sales ($m) Forecast, EVAR, 2011-2020
  • Table 105: South America Aortic Stent Grafts Sales ($m) Forecast, TEVAR, 2011-2020
  • Table 106: Aortic Stent Grafts Sales ($m) Forecast for Brazil, 2011-2020

List of Figures

  • Figure 1: Treatment Methodology Markov Model
  • Figure 2: Aortic Stent Graft Product Image
  • Figure 3: South America Abdominal Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 4: South America Thoracic Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 5: South America Aortic Stent Grafts Sales ($m) Forecast, EVAR, 2011-2020
  • Figure 6: South America Aortic Stent Grafts Sales ($m) Forecast, TEVAR, 2011-2020
  • Figure 7: Brazil Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 8: Aortic Stent Graft Primary Research, Supply and Demand-Side Interviews
Back to Top